Patients with Diffuse Large B-Cell Lymphoma: We Need Your Help!
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Quebec equivalent INESSS (Institut national d’excellence en santé et services sociaux) for an upcoming drug review on Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy, for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) in the second-line setting.
If you have DLBCL and have received this treatment as a second-line therapy, you can help by completing our survey. You can still participate in this survey if you have received this treatment in a different line of therapy or if you have not received this therapy. You do not need to have relapsed or refractory DLBCL to participate.
The survey provides us with the patient input required for the submission. CADTH uses this information to help them write recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Monday, June 20, and should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.